4 Stocks You'll Wish You Bought on This Dip (One Is Down Over 50%)

Get the FREE Phase Two AI Report of the next AI stocks most of the market isn't paying attention to yet: https://www.marketbeat.com/y/yt1028/ Buying the dip is one of the oldest ways to build wealth in the stock market... and right now there are a lot of chances to do it. Alexander Green, Chief Investment Strategist at the Oxford Club, joins MarketBeat with four buy the dip stocks to buy now, all trading well below their highs. Alexander explains why so much of the market is chasing the same handful of mega cap stocks, and why the best opportunities may be in the other 492 stocks in the S&P 500, in small cap stocks and in international stocks. He also breaks down what money manager Ken Fisher calls the "midterm miracle." Over the last 100 years, the nine months after the midterm elections have been the strongest nine months for the stock market, with an average gain of 19.5%... no matter who wins. His list covers the leader in Latin American e-commerce, a GLP-1 weight loss drug maker trading at less than 10 times earnings with a big dividend, a software company making government more efficient, and a speculative biotech stock with an FDA decision coming in November. Plus, he explains how he uses a trailing stop to let profits run and cut losses short. Chapters 0:00 Introduction 1:57 The Midterm Miracle 5:31 Stock 1 10:11 Stock 2 15:20 Stocks 3 18:30 Stock 4 21:36 How to Use a Trailing Stop View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks. For YouTube sponsorships, brand partnerships and advertising, send an email to: [email protected] DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.